Animal Drug User Fee Act; Public Meeting; Request for Comments
Details
The document's own metadata, straight from the source system.
- Title
- Animal Drug User Fee Act; Public Meeting; Request for Comments
- Posted
- Apr 17, 2026
- Comment period
- Apr 17, 2026 – Dec 2, 2027
- FR Doc
- 2026-07498
- Topics
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Stance breakdown
Who commented
Breakdown by commenter type.
Comments over time
Weekly arrivals, stacked by stance.
Support × commenter type
How each type splits across stance.
Issues raised
The docket's canonical issues. Select one to browse its comments.
Position map
Who stands where on each issue?
Every non-silent position is backed by an excerpt from the comment.
Issues shown
Choose up to five.
| Organization | Adufa reauthorization | Modernization of animal drug review |
|---|
2 organization-typed comments could not be identified.
Campaigns
Organized form-letter drives, separated from organic one-off comments.
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
- Jun 28, 2026Comment from Sewright KathleenSupportIndividual
The commenter supports the reauthorization of the Animal Drug User Fee Act (ADUFA) but argues that the FDA should seek greater authority from Congress to address antibiotic resistance and public health risks. They specifically advocate for the ability to require label changes for animal drugs when specific uses pose a risk.
Read comment → - Jun 24, 2026Comment from Miller MeredithSupportIndividual
The commenter supports the reauthorization of the Animal Drug User Fee Act (ADUFA) but argues that the FDA should seek greater authority from Congress to address antibiotic resistance and public health risks. They specifically advocate for the ability to require label changes for animal drugs when specific uses pose a risk.
Read comment → - Jun 23, 2026Comment from Swoboda TammySupportIndividual
The commenter supports the reauthorization of the Animal Drug User Fee Act (ADUFA) but argues that the FDA should seek greater authority from Congress to address antibiotic resistance and public health risks. They specifically advocate for the ability to require label changes for animal drugs when specific uses pose a risk.
Read comment → - Jun 23, 2026Comment from Garvin AdeleSupportIndividual
The commenter supports the reauthorization of the Animal Drug User Fee Act (ADUFA) but argues that the FDA should seek greater authority from Congress to address antibiotic resistance and public health risks. They specifically advocate for the ability to require label changes for animal drugs when specific uses pose a risk.
Read comment → - Jun 23, 2026Comment from Klucsar BarbaraSupportIndividual
The commenter supports the reauthorization of the Animal Drug User Fee Act (ADUFA) but argues that the FDA should seek greater authority from Congress to address antibiotic resistance and public health risks. They specifically advocate for the ability to require label changes for animal drugs when specific uses pose a risk.
Read comment → - Jun 23, 2026Comment from SHEA KathleenSupportIndividual
The commenter supports the reauthorization of the Animal Drug User Fee Act (ADUFA) but argues that the FDA should seek greater authority from Congress to address antibiotic resistance and public health risks. They specifically advocate for the ability to require label changes for animal drugs when specific uses pose a risk.
Read comment → - Jun 22, 2026Comment from martinez priscillaSupportIndividual
The commenter supports the reauthorization of the Animal Drug User Fee Act (ADUFA) but argues that the FDA should seek greater authority from Congress to address antibiotic resistance and public health risks. They specifically advocate for the ability to require label changes for animal drugs when specific uses pose a risk.
Read comment → - Jun 22, 2026Comment from Robb AaeronSupportIndividual
The commenter supports the reauthorization of the Animal Drug User Fee Act (ADUFA) but argues that the FDA should seek greater authority from Congress to address antibiotic resistance and public health risks. They specifically advocate for the ability to require label changes for animal drugs when specific uses pose a risk.
Read comment → - Jun 22, 2026Comment from maxfield caseeSupportIndividual
The commenter supports the reauthorization of the Animal Drug User Fee Act (ADUFA) but argues that the FDA should seek greater authority from Congress to address antibiotic resistance and public health risks. They specifically advocate for the ability to require label changes for animal drugs when specific uses pose a risk.
Read comment → - Jun 22, 2026Comment from Hondo MicheleSupportIndividual
The commenter supports the reauthorization of the Animal Drug User Fee Act (ADUFA) but argues that the FDA should seek greater authority from Congress to address antibiotic resistance and public health risks. They specifically advocate for the ability to require label changes for animal drugs when specific uses pose a risk.
Read comment →